21.02.2020 • NewsDede WillamsMitsubishiTaiwan

Mitsubishi to Build Hydrogen Peroxide Plant in Taiwan

Mitsubishi to Build Hydrogen Peroxide Plant in Taiwan (c) mmmx/Shutterstock
Mitsubishi to Build Hydrogen Peroxide Plant in Taiwan (c) mmmx/Shutterstock

Mitsubishi Gas Chemical (MGC) is building a new 40,000 t/y plant for 100% industrial hydrogen peroxide (IHP) at a site owned by a subsidiary in Taiwan. The facility is expected to start up at the beginning of 2023.

The Japanese company said the investment is part of its plans to further develop its business with super-pure hydrogen peroxide (SPHP) used in semiconductor production processes, with the goal of participating in the long-term global growth of the semiconductor industry.

SPHP is used primarily as a cleaning, etching and abrading agent in semiconductor wafer and device manufacturing processes, which are expected to see long-term growth in line with  to future advancements in 5G, IoT, cloud computing, AI and other technologies.

The company sees demand as also as rising on the back of the trend to increasing miniaturization in semiconductor wiring processes, where greater volumes of SPHP featuring even higher quality will be needed.

MGC currently operates three SPHP production sites in Japan – at Yokkaichi, Yamakita and Saga – along with two in South Korea, three in the US and one each in Singapore and Taiwan.

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.